• linkedin
  • Increase Font
  • Sharebar

    Biosimilar: Coming to a pharmacy near you

    After brisk sales through specialty pharmacy, biosimilars are moving toward community pharmacy. Basaglar (insulin glargine injection; Lilly, Boehringer Ingelheim), the first FDA-approved follow-on recombinant insulin, could hit pharmacy shelves in December.

    Manufacturers have been prepping for years. About half of the states have enacted statutory or regulatory frameworks for biosimilar substitution. Nearly all were written and sponsored by industry, with little or no input from pharmacy.

    Pharmacy benefit managers and payers have been positioning biologics, such as Lantus (insulin glargine injection, Sanofi-Aventis), Neupogen (filgrastim, Amgen), and Remicade (infliximab, Johnson & Johnson), to take advantage of biosimilar competition from Basaglar, Zarxio (filgrastim-sndz, Novartis), and Inflectra (infliximab-dyyb, Celltrion). Industry observers count another 50-plus biosimilars in the FDA approval process.

    “Biosimilars are the future of pharmacy,” said Jillanne Schulte, director of federal regulatory affairs for the American Society of Health-System Pharmacists. “We are seeing the forefront of the coming wave of innovation in health care. When biosimilars hit community pharmacy, issues like interchangeability that have been important in specialty settings are going to explode. Biosimilars are the frontier of medicine.”

    Biosimilar, not generic

    Biosimilars have been a staple in European healthcare for a decade. The European Medicines Agency (EMA) created its biosimilars pathway in 2005 and has approved at least 19 biosimilars in six product categories: epoetins, filgrastims, follitropins, growth hormones, insulins, and monoclonal antibodies.

    EMA-approved biosimilars are priced about 30% below the reference product, according to Express Scripts. The PBM projects US savings of nearly $22.7 billion by 2024 from the approval of Zarxio and Inflectra and $250 billion from a basket of 11 biosimilars currently awaiting FDA approval.

    Fred Gebhart, Contributing Editor
    Contributing Editor Fred Gebhart works all over the world as a freelance writer and editor, but his home base is in San Francisco.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available
    Slideshows
    Small Doses: The Weekly News You Need to Know
    Small Doses: The Weekly News You ...

    Small doses is a weekly slideshow of the news you may have missed, made just for you and your busy lifestyle.

    25 Cities With The Lowest Pharmacist ...
    Strange, offbeat, and obscure ...